Lysine demethylase inhibitors for diseases and disorders associated with <i>Hepadnaviridae</i>

摘要

The present invention provides for the treatment or prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae infection. In particular, the invention provides compositions and methods that affect the ability of Hepadnaviridae to utilize the host's cellular machinery as part of the virus' lifecycle. The invention relates to the discovery that interfering with the normal ability of viruses to utilize the host cell machinery with LSD1 inhibitors reduces HBV replication. Thus, the treatment and prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae according to the invention comprises administering to an individual in need of treatment, a therapeutically effective amount of a LSD1 inhibitor. The individual in need of treatment can be a human or, e.g., another mammal.

主权项

1. A method of treating a Hepadnaviridae infection or a disease or disorder associated with Hepadnaviridae chosen from Hepatitis B and liver cancer, the method comprising administering to an individual in need of such treatment a therapeutically effective amount of an LSD1 (lysine specific demethylase-1) inhibitor, wherein the LSD1 inhibitor is a phenylcyclopropylamine derivative or analog, a phenelzine derivative or analog, or a propargylamine derivative or analog.